CASTELLAZZI, Massimiliano
 Distribuzione geografica
Continente #
NA - Nord America 8.312
EU - Europa 2.512
AS - Asia 1.869
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 14
Totale 12.726
Nazione #
US - Stati Uniti d'America 8.286
CN - Cina 923
IT - Italia 516
UA - Ucraina 493
SG - Singapore 463
PL - Polonia 411
TR - Turchia 329
DE - Germania 326
GB - Regno Unito 269
FI - Finlandia 176
SE - Svezia 129
ID - Indonesia 56
AT - Austria 46
CZ - Repubblica Ceca 34
BE - Belgio 32
FR - Francia 29
HK - Hong Kong 28
CA - Canada 24
VN - Vietnam 21
IR - Iran 20
AU - Australia 18
NL - Olanda 12
A2 - ???statistics.table.value.countryCode.A2??? 8
IN - India 8
KR - Corea 8
LT - Lituania 7
EU - Europa 6
IQ - Iraq 5
PT - Portogallo 5
RO - Romania 5
ES - Italia 4
HU - Ungheria 3
IE - Irlanda 3
JP - Giappone 3
RU - Federazione Russa 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
AL - Albania 1
EE - Estonia 1
GE - Georgia 1
GR - Grecia 1
HN - Honduras 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
SV - El Salvador 1
TW - Taiwan 1
Totale 12.726
Città #
Woodbridge 1.121
Fairfield 905
Chandler 713
Houston 578
Ashburn 568
Jacksonville 560
Santa Clara 491
Warsaw 399
Ann Arbor 391
Singapore 377
Wilmington 328
Seattle 317
Cambridge 294
Izmir 223
Ferrara 202
Nanjing 187
Beijing 159
Princeton 153
Milan 120
New York 108
Boardman 107
Shanghai 92
San Diego 87
Dearborn 77
Addison 65
Helsinki 58
Los Angeles 57
Jakarta 55
Nanchang 55
Shenyang 48
Bremen 47
Tianjin 45
Vienna 45
Hebei 42
Jiaxing 42
Changsha 41
Norwalk 37
Brussels 32
Brno 29
Hong Kong 28
Falls Church 26
London 23
Redwood City 22
San Mateo 21
Dong Ket 20
Jinan 20
Ningbo 20
Auburn Hills 19
Orange 19
Mountain View 17
Zhengzhou 17
Bologna 16
Washington 16
Guangzhou 14
Munich 14
Toronto 14
Kunming 13
Frankfurt am Main 12
Des Moines 11
Tappahannock 11
Indiana 10
Falkenstein 9
Ferrara di Monte Baldo 9
Kraków 9
Ottawa 9
Taizhou 9
Verona 9
Leawood 8
Padova 8
Ardabil 7
Hefei 7
Philadelphia 7
Redmond 7
Changchun 6
Monmouth Junction 6
Rome 6
Hangzhou 5
Melbourne 5
Olomouc 5
Amsterdam 4
Andover 4
Augusta 4
Cagliari 4
Fuzhou 4
Haikou 4
Lanzhou 4
Madison 4
Turin 4
Yellow Springs 4
Berlin 3
Calderara Di Reno 3
Chicago 3
Clifton 3
Hounslow 3
Kilburn 3
Reggio Emilia 3
Sant'elena 3
Serpa 3
Shaoxing 3
Stockholm 3
Totale 9.842
Nome #
Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment 346
Decreased Arylesterase activity of Paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases 176
Epstein-Barr virus and Multiple Sclerosis: in-depth analysis of the virus-specific antibody response at the time of diagnosis and during therapy 173
TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis 161
Comparison of antibodies with amylase activity from cerebrospinal fluid and serum of patients with multiple sclerosis 157
Evaluation of total, ceruloplasmin-associated and type II ferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients 150
Multiple Sclerosis in Italy: A 40-Year Follow-Up of the Prevalence in Ferrara 148
Timing of serum active MMP-9 and MMP-2 levels in acute and subacute phases after spontaneous intracerebral hemorrhage 147
Autophagy and mitophagy elements are increased in body fluids of multiple sclerosis-affected individuals 145
A Commentary on the Use of Epstein-Barr Virus Specific Antibodies as Biological Markers in Multiple Sclerosis 144
Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis 143
Emerging topics and new perspectives on HLA-G 140
Comparison of DNA-Hydrolyzing Antibodies from the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis 137
Matrix metalloproteinase 9 as a marker of disease activity in multiple sclerosis 134
Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker 134
Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies 134
Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis Patients 131
Cerebrospinal fluid analysis and the determination of oligoclonal bands 130
Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis 129
Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA class I molecules 129
Detection of antibodies directed against human herpesvirus 6 U94/REP in sera of patients affected by multiple sclerosis 126
Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis 124
Epidemiological health and social study on multiple sclerosis in the Ferrara province 124
Intrathecal Soluble HLA-E Correlates with Disease Activity in Patients with Multiple Sclerosis and may Cooperate with Soluble HLA-G in the Resolution of Neuroinflammation. 124
Correlation between auto/mitophagic processes and magnetic resonance imaging activity in multiple sclerosis patients 123
Chlamydia pneumoniaespecific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms 121
Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy 119
Autophagy and mitophagy biomarkers are reduced in sera of patients with Alzheimer's disease and mild cognitive impairment 119
Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis 114
Assessment of HIV-intrathecal humoral immune response in AIDS-related neurological disorders 113
Matrix metalloproteinase-9 activity detected in body fluids is the result of two different enzyme forms 111
null 110
null 109
Intrathecal levels of vitamin D and IgG in multiple sclerosis 106
Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding 106
Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings 106
null 104
Investigation of the prevalence of antibodies against neurotropic polyomaviruses BK, JC and SV40 in sera from patients affected by multiple sclerosis 104
null 102
Intrathecal production of Chlamydia pneumoniae-specific high-affinity antibodies is significantly associated to a subset of multiple sclerosis patients with progressive forms 102
A proteomic approach to detect gelatinases levels and their inhibitors in patients with neurological diseases 101
ERMES: EMILIA ROMAGNA MULTIPLE SCLEROSIS. REGIONAL NETWORK FOR IMPLEMENTING A BIOLOGICAL BANK TO IDENTIFY MARKERS OF DISEASE ACTIVITY RELATED TO CLINICAL VARIABLES Identification of a TIMP-1-resistant active MMP-9 in serum of Multiple Sclerosis patients 99
Affinity distribution of anti-EBV IgG in the cerebrospinal fluid of patients with multiple sclerosis and in controls 99
null 97
null 97
Effect of pH on MMP-9 release by LPS-stimulated neutrophils 96
null 96
Clinical and MRI activity are associated to elevated cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-9 in multiple sclerosis patients 96
Timing of serum soluble HLA-G levels in acute and subacute phases after spontaneous intracerebral hemorrhage. 96
A Further Evidence Of Pathogenic Role Of Chlamydia Pneumoniae In Multiple Sclerosis 95
Neurofilament ELISA validation 95
A new developed culture method efficiently supports the growth of Chamydia pneumoniae in PBMC and CSF samples from patients with Multiple Sclerosis 95
DNA Sequences of Parachlamydia-like organisms in CSF of Patients with Neurological Disorders 94
Multiplex Matrix Metalloproteinases Analysis in the Cerebrospinal Fluid Reveals Potential Specific Patterns in Multiple Sclerosis Patients 92
CEREBROSPINAL FLUID AND SERUM LEVELS OF ANTI-CHLAMYDIA PNEUMONIAE IGA IN PATIENTS WITH MULTIPLE SCLEROSIS 92
Matrix Metalloproteinases as a Pleiotropic Biomarker in Medicine and Biology 90
null 90
null 88
Decrease Paraoxonase-1 (PON-1) Activities in Neurodegenerative Diseases 88
Quantification of CSF and serum levels and intrathecal synthesis of anti-EBV antibodies in patients with multiple sclerosis and with other neurological disorders. 88
null 87
Increased age and male sex are independently associated with higher frequency of blood-cerebrospinal fluid barrier dysfunction using the albumin quotient 87
Matrix metalloproteinases (MMP): determination of different forms by different techniques may require different preanalytical strategies 86
An overview on the relationship between Epstein-Barr virus and multiple sclerosis 86
SERUM GELATINASES LEVELS IN MULTIPLE SCLEROSIS PATIENTS DURING 21 MONTHS OF NATALIZUMAB TREATMENT 85
null 84
ERMES: EMILIA ROMAGNA MULTIPLE SCLEROSIS. REGIONAL NETWORK FOR THE IMPLEMENTATION A BIOLOGICAL BANK TO IDENTIFY MARKERS OF DISEASE ACTIVITY RELATED TO CLINICAL VARIABLES IN MS. 84
null 84
INTRATHECAL PRODUCTION OF ACTIVE FORM OF MATRIX METALLOPROTEINASES-9 IN PATIENTS WITH MULTIPLE SCLEROSIS: PRELIMINARY RESULTS” 84
Intrathecal synthesis of interleukin-12 in multiple sclerosis 82
25 hydroxyvitamin D in cerebrospinal fluid from patients with multiple sclerosis during relapse and remission 81
Biomolecular and immunological diagnostic aspects of toxoplasmosis during AIDS. 81
Inverse association between CSF levels of solubile HLA-G and Fas molecules in MS patients with no evidence of MRI disease activity. 79
25-hydroxyvitamin D in cerebrospinal fluid from patients with multiple sclerosis 79
Analysis of MMP-9 in CSF and sera of patients with neurological diseases 78
Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 are elevated in in multiple sclerosis patients with disease activity 77
Influence of different strategies of volume replacement on the activity of matrix metalloproteinases: an in vitro and in vivo study 76
Cerebrospinal fluid oligoclonal free light chain profiles in AIDS 76
null 75
Increased Levels of Endothelin-1 in Cerebrospinal Fluid Are a Marker of Poor Visual Recovery after Optic Neuritis in Multiple Sclerosis Patients 74
N-acetylaspartate, glutammate and aspartate levels in multiple sclerosis cerebrospinal fluid. 73
Chlamydia pneumonia-specific CFS-restricted oligoclonal IgG bands are associated to a subset of patients with prosessive forms of multiple sclerosis. 72
Multiple Sclerosis and HERV-W/MSRV: A Multicentric Study. Int J Biomed Sci. 72
Elevated CSF and serum levels and intrathecal synthesis of active MMP-2 in MS patients with no evidence of MRI disease activity 72
Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study 72
Under the microscope: Focusing on Chlamydia pneumoniae infection and Multiple Sclerosis 71
Cerebrospinal fluid free Kappa and Lambda lights chains in MS. A qualitative analysis 70
Comparative analysis of environmental effects on multiple sclerosis development in Russian and Italian ethnic groups. 69
Altered miRNA expression in T regulatory cells in course of multipla sclerosis 69
null 68
An evaluation of quantitative env and qualitative pol rt-pcr detection of the multiple sclerosis (MS) -associated retrovirus in Europe 68
Detection of serum soluble HLA-G levels in patients with acute ischemic stroke: a pilot study 68
Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis 68
Le alterazioni liquorali nella neurosifilide sintomatica. 67
Potential role of soluble HLA-G molecules in multiple sclerosis 67
Gelatinase: enzymatic activity as potential biomarker in multiple sclerosis 67
Matrix metalloproteinase-2 (MMP-2) immune functions via surface proteolytic shedding of HLA-G1 molecules 66
null 66
Inflammation and axonal damage biomarkers in Multiple Sclerosis: new perspective on their role 66
Gelatinases: enzymatic activity as potential biomarker in multiple sclerosis 66
Totale 10.241
Categoria #
all - tutte 62.740
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 597
Totale 63.337


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.389 0 0 0 0 0 283 217 250 190 289 112 48
2020/20211.659 141 110 76 160 80 152 53 205 64 271 241 106
2021/20221.327 34 162 74 57 44 60 60 65 53 122 95 501
2022/20231.599 154 138 35 236 252 230 117 152 166 6 73 40
2023/2024956 79 88 45 25 101 187 27 85 35 25 28 231
2024/20251.316 76 79 275 142 447 297 0 0 0 0 0 0
Totale 12.981